Chemotherapy regimens with immunotherapy in advanced gastric cancer: A prognostic study using Cox modeling

Figure 1 Comparison of progression-free survival and overall survival among the three groups. A: Progression-free survival; B: Overall survival. FOLFOX: Oxaliplatin plus leucovorin and fluorouracil; OS: Overall survival; PFS: Progression-free survival; PSOX: Plus oxaliplatin and S-1; SOX + XDL: S-1 combined with sintilimab and oxaliplatin.

Figure 2 Least absolute shrinkage and selection operator regression analysis. A: Least absolute shrinkage and selection operator regression with 10-fold cross-validation for selection of the optimal penalty parameter; B: Least absolute shrinkage and selection operator coefficient profiles of candidate variables as a function of log(λ).

Figure 3 Least absolute shrinkage and selection operator -selected predictors and their corresponding coefficients. RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor regression grade.

Figure 4 Progression-free survival nomogram. PFS: Progression-free survival; RECIST: Response Evaluation Criteria in Solid Tumors; TRG: Tumor regression grade.

Figure 5 Progression-free survival receiver operating characteristic curve. A: 18-month, 24-month, 36-month training set; B: 18-month, 24-month, 36-month validation set. AUC: Area under the curve.

Figure 6 Calibration curve for progression-free survival. A: 18-month training set; B: 24-month training set; C: 36-month training set; D: 18-month validation set; E: 24-month validation set; F: 36-month validation set.

Figure 7 Decision curve analysis curves of progression-free survival. A: 18-month training set; B: 24-month training set; C: 36-month training set; D: 18-month validation set; E: 24-month validation set; F: 36-month validation set.